India
· Delayed Price · Currency is INR Neuland Laboratories Statistics
Total Valuation
Neuland Laboratories has a market cap or net worth of INR 161.66 billion. The enterprise value is 161.74 billion.
| Market Cap | 161.66B |
| Enterprise Value | 161.74B |
Important Dates
The next estimated earnings date is Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | Jul 12, 2024 |
Share Statistics
Neuland Laboratories has 12.83 million shares outstanding. The number of shares has decreased by -0.01% in one year.
| Shares Outstanding | 12.83M |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 37.38% |
| Owned by Institutions (%) | 16.83% |
| Float | 7.01M |
Valuation Ratios
The trailing PE ratio is 48.10 and the forward PE ratio is 56.02.
| PE Ratio | 48.10 |
| Forward PE | 56.02 |
| PS Ratio | 9.89 |
| PB Ratio | 12.60 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 48.13 |
| EV / Sales | 9.89 |
| EV / EBITDA | 33.18 |
| EV / EBIT | 37.87 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 7.44 |
| Debt / EBITDA | 0.20 |
| Debt / FCF | n/a |
| Interest Coverage | 37.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 21.35% |
| Revenue Per Employee | 9.95M |
| Profits Per Employee | 2.05M |
| Employee Count | 1,643 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +248.83% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +248.83% |
| 50-Day Moving Average | 10,216.53 |
| 200-Day Moving Average | 7,242.61 |
| Relative Strength Index (RSI) | 65.66 |
| Average Volume (20 Days) | 4,746 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neuland Laboratories had revenue of INR 16.35 billion and earned 3.36 billion in profits. Earnings per share was 261.94.
| Revenue | 16.35B |
| Gross Profit | 8.72B |
| Operating Income | 4.27B |
| Pretax Income | 4.48B |
| Net Income | 3.36B |
| EBITDA | 4.84B |
| EBIT | 4.27B |
| Earnings Per Share (EPS) | 261.94 |
Balance Sheet
The company has 875.75 million in cash and 953.90 million in debt, giving a net cash position of -78.14 million or -6.09 per share.
| Cash & Cash Equivalents | 875.75M |
| Total Debt | 953.90M |
| Net Cash | -78.14M |
| Net Cash Per Share | -6.09 |
| Equity (Book Value) | 12.83B |
| Book Value Per Share | 999.78 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 53.32%, with operating and profit margins of 26.12% and 20.55%.
| Gross Margin | 53.32% |
| Operating Margin | 26.12% |
| Pretax Margin | 27.40% |
| Profit Margin | 20.55% |
| EBITDA Margin | 29.61% |
| EBIT Margin | 26.12% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 14.00, which amounts to a dividend yield of 0.11%.
| Dividend Per Share | 14.00 |
| Dividend Yield | 0.11% |
| Dividend Growth (YoY) | 40.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.12% |
| Earnings Yield | 2.08% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |